{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:03:55Z","timestamp":1777658635372,"version":"3.51.4"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.28627","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T01:17:55Z","timestamp":1607563075000},"page":"e2028627","source":"Crossref","is-referenced-by-count":34,"title":["Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016"],"prefix":"10.1001","volume":"3","author":[{"given":"Weiye","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, School of Public Health, the University of Texas Health Science Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieqiong","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaogang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"An","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina N.","family":"Sanford","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty Y. S.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"issue":"1","key":"zoi200916r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v69.1","article-title":"Cancer statistics, 2019.","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"zoi200916r2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jso.23512","article-title":"Treatment of metastatic melanoma with electrochemotherapy.","volume":"109","author":"Campana","year":"2014","journal-title":"J Surg Oncol"},{"issue":"5","key":"zoi200916r3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1586\/era.11.25","article-title":"Therapy for metastatic melanoma: an overview and update.","volume":"11","author":"Boyle","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"zoi200916r4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.","volume":"33","author":"Maio","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi200916r5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdermsci.2014.02.007","article-title":"The risk of developing a second primary cancer in melanoma patients: a comprehensive review of the literature and meta-analysis.","volume":"75","author":"Caini","year":"2014","journal-title":"J Dermatol Sci"},{"issue":"30","key":"zoi200916r6","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1200\/JCO.2012.41.8681","article-title":"Second malignant neoplasms: assessment and strategies for risk reduction.","volume":"30","author":"Wood","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi200916r7","doi-asserted-by":"publisher","first-page":"e181999","DOI":"10.1001\/jamanetworkopen.2018.1999","article-title":"Trends in risks for second primary cancers associated with index human papillomavirus\u2013associated cancers.","volume":"1","author":"Suk","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi200916r8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jid.2018.11.001","article-title":"Risk of second primary cancer in survivors of in situ melanoma.","volume":"139","author":"Kimlin","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"12","key":"zoi200916r9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1001\/archdermatol.2011.1133","article-title":"Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer.","volume":"147","author":"Yang","year":"2011","journal-title":"Arch Dermatol"},{"issue":"1","key":"zoi200916r10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jamaoncol.2017.2395","article-title":"Change in pattern of secondary cancers after Kaposi sarcoma in the era of antiretroviral therapy.","volume":"4","author":"Mukhtar","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi200916r11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jaad.2019.10.024","article-title":"Risk of second primary cutaneous and noncutaneous melanoma after cutaneous melanoma diagnosis: a population-based study.","volume":"82","author":"Beroukhim","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"zoi200916r12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1001\/jamaoncol.2018.6862","article-title":"Incidence of and risk factors for histologically confirmed solid benign tumors among long-term survivors of childhood cancer.","volume":"5","author":"Kok","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi200916r13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bjh.2017.178.issue-1","article-title":"Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.","volume":"178","author":"Tao","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"zoi200916r14","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.jaad.2011.04.033","article-title":"Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin.","volume":"65","author":"Balamurugan","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"zoi200916r15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis.","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front Oncol"},{"key":"zoi200916r16","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3389\/fimmu.2017.01547","article-title":"Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract.","volume":"8","author":"Dougan","year":"2017","journal-title":"Front Immunol"},{"issue":"22","key":"zoi200916r17","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"zoi200916r18","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi200916r19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"zoi200916r20","doi-asserted-by":"publisher","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"issue":"17","key":"zoi200916r21","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline.","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"zoi200916r22","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1002\/cncr.v126.23","article-title":"Abrogation of survival disparity between Black and White individuals after the USPSTF\u2019s 2012 prostate-specific antigen-based prostate cancer screening recommendation.","volume":"126","author":"Kim","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"zoi200916r23","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ijc.v145.6","article-title":"Excess HPV-related head and neck cancer in the world trade center health program general responder cohort.","volume":"145","author":"Graber","year":"2019","journal-title":"Int J Cancer"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2773829\/deng_2020_oi_200916_1606921688.30892.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T01:17:56Z","timestamp":1607563076000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2773829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.28627","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,9]]}}}